Brain Metastases
Brain metastases are the most common intracranial tumors in adults, outnumbering primary brain tumors by approximately 10:1. An estimated 20–40% of patients with systemic cancer will develop brain metastases during the course of their disease, with incidence rising as systemic therapies improve and patients survive longer. The management of brain metastases has undergone a paradigm shift over the past decade, moving from whole-brain radiation as the default treatment to increasingly individualized approaches incorporating stereotactic radiosurgery, targeted systemic therapies that cross the blood-brain barrier, and immunotherapy. The neurologist plays a critical role in the multidisciplinary management of these patients — from initial diagnosis through treatment-related complications and end-of-life care.
Bottom Line
- Epidemiology: Most common intracranial tumors; lung cancer is the most common primary, followed by breast, melanoma, renal cell, and colorectal
- Distribution: ~80% cerebral hemispheres, ~15% cerebellum, ~5% brainstem; predilection for gray-white matter junction (hematogenous spread)
- Hemorrhagic metastases: Melanoma, renal cell carcinoma, choriocarcinoma, thyroid carcinoma (“MR CT” mnemonic)
- Single vs solitary: Single = one brain metastasis with known systemic cancer; solitary = one brain metastasis as the only known site of disease
- Limited metastases (1–4): Surgery + SRS, or SRS alone, depending on size, location, and histology
- Multiple metastases: WBRT with hippocampal avoidance + memantine (NRG CC001); SRS may be feasible for up to 10–15 lesions at select centers
- Systemic therapies: CNS-penetrant targeted agents (osimertinib for EGFR+ NSCLC, tucatinib for HER2+ breast) and immunotherapy (ipilimumab + nivolumab for melanoma) have transformed outcomes for specific histologies
- Steroids: Dexamethasone for peritumoral edema; taper as soon as feasible to minimize toxicity
Epidemiology and Common Primary Tumors
| Primary Cancer | Frequency Among Brain Mets | Key CNS Features | Molecular Subtypes with CNS Tropism |
|---|---|---|---|
| Lung (NSCLC + SCLC) | ~40–50% | Most common cause; may be presenting feature (especially NSCLC); SCLC has high CNS recurrence | EGFR-mutant, ALK-rearranged, ROS1, KRAS G12C |
| Breast | ~15–25% | HER2+ and triple-negative subtypes have highest CNS risk; may present years after initial diagnosis | HER2+, triple-negative (TNBC) |
| Melanoma | ~5–15% | Up to 60% develop brain mets; frequently hemorrhagic; often multiple | BRAF V600E (~50%), NRAS |
| Renal cell carcinoma | ~5–10% | Hemorrhagic; often large, solitary; resistant to conventional radiation | Clear cell (VHL-mutant) |
| Colorectal | ~3–5% | Less common; often posterior fossa; typically late in disease course | MSI-high (immune checkpoint responsive) |
Pathophysiology and Distribution
Metastatic Cascade to the Brain
Brain metastases develop through hematogenous dissemination. Tumor cells must complete a multistep process: intravasation into systemic circulation, survival in the bloodstream, arrest at the blood-brain barrier (BBB), extravasation into brain parenchyma, and establishment of a microenvironment supporting growth. The BBB is disrupted in established metastases, allowing contrast enhancement on imaging, but the blood-tumor barrier remains variably permeable — which has major implications for drug delivery.
Anatomic Distribution
- Cerebral hemispheres: ~80% of brain metastases; proportional to blood flow (MCA territory most common)
- Cerebellum: ~15%; posterior fossa metastases carry risk of obstructive hydrocephalus and tonsillar herniation
- Brainstem: ~5%; difficult surgical target; SRS is the primary treatment modality
- Gray-white junction: Preferential location due to narrowing of blood vessels at this interface, causing tumor cell arrest
- Watershed zones: Terminal arteriolar fields trap tumor emboli
Hemorrhagic Brain Metastases
Tumors Prone to Hemorrhagic Metastases (“MR CT”)
- Melanoma — most hemorrhagic of all brain metastases
- Renal cell carcinoma
- Choriocarcinoma
- Thyroid carcinoma
- Hemorrhage may be the presenting event; acute intratumoral hemorrhage can mimic primary intracerebral hemorrhage or hemorrhagic stroke
- Consider metastatic disease in any patient with hemorrhagic brain lesion and known cancer history, or in older patients with lobar hemorrhage and no clear vascular etiology
Clinical Presentation
- Headache: ~50% of patients; typically progressive, worse in the morning, exacerbated by Valsalva; may be caused by mass effect, edema, or hydrocephalus
- Focal neurologic deficits: Hemiparesis, aphasia, visual field deficits, ataxia — depend on location
- Seizures: 15–25% at presentation; more common with cortical and melanoma metastases; levetiracetam is preferred (fewer drug-drug interactions with chemotherapy); prophylactic antiseizure medication is NOT recommended
- Cognitive/behavioral changes: Especially with frontal lobe and multiple metastases; may be subtle initially
- Acute presentations: Hemorrhage into metastasis, acute obstructive hydrocephalus (posterior fossa lesions), seizures
Imaging and Diagnosis
MRI Features
Characteristic MRI Findings
- T1-weighted post-contrast: Ring-enhancing or solid enhancing lesions at the gray-white junction; enhancement reflects BBB disruption
- FLAIR: Surrounding vasogenic edema, often disproportionate to the size of the enhancing lesion
- T2*/SWI: Hemorrhagic components appear as areas of blooming artifact (melanoma, renal, choriocarcinoma)
- DWI: Variable; central restricted diffusion may indicate necrosis or high cellularity
- T1 hyperintensity (pre-contrast): Characteristic of melanotic melanoma metastases (paramagnetic melanin) and hemorrhagic lesions
- Multiplicity: Multiple ring-enhancing lesions at the gray-white junction in a patient with known cancer is highly suggestive of metastatic disease
Differential Diagnosis of Ring-Enhancing Lesions
| Diagnosis | Key Distinguishing Features |
|---|---|
| Brain metastasis | Multiple lesions, gray-white junction, known cancer, disproportionate edema |
| Brain abscess | Restricted diffusion centrally (pus); smooth, thin enhancing rim; systemic infection source |
| High-grade glioma (GBM) | Usually single, irregular enhancing rim, infiltrative, crosses corpus callosum (“butterfly”) |
| Demyelination (tumefactive MS) | Incomplete ring enhancement (“open ring”), young patient, minimal mass effect for size |
| Lymphoma | Periventricular, homogeneous enhancement (immunocompetent), restricted diffusion, disappears with steroids |
| Radiation necrosis | Within prior radiation field; similar appearance to recurrent tumor; MR perfusion/spectroscopy/PET may help distinguish |
Advanced Imaging
- MR perfusion (DSC): Elevated rCBV in tumor recurrence vs low rCBV in radiation necrosis
- MR spectroscopy: Elevated choline/NAA ratio suggests tumor; elevated lipid-lactate peak in necrosis
- PET imaging: FDG-PET has limited utility in brain (high background uptake); amino acid PET (FET-PET, MET-PET) better differentiates recurrence from treatment effects
Tissue Diagnosis
- Biopsy is not always necessary if imaging is classic and systemic cancer is known
- Indications for biopsy/resection: No known primary cancer, solitary lesion with diagnostic uncertainty, atypical imaging features, need for molecular profiling
- Molecular profiling of brain metastases may reveal actionable mutations (sometimes discordant from the primary tumor)
Prognostic Assessment
Graded Prognostic Assessment (GPA)
The diagnosis-specific GPA (DS-GPA) is the most widely used and validated prognostic tool for brain metastases. It provides histology-specific prognostic scores incorporating different variables depending on the primary cancer type:
| Primary Tumor | Prognostic Variables in DS-GPA | Median Survival Range |
|---|---|---|
| NSCLC | Age, KPS, number of brain mets, extracranial mets, EGFR/ALK status | 3–47 months |
| Breast | Age, KPS, tumor subtype (HER2+, HR+/HER2−, TNBC) | 4–36 months |
| Melanoma | Age, KPS, number of brain mets, extracranial mets, BRAF status | 5–34 months |
| Renal cell | KPS, number of brain mets, extracranial mets, hemoglobin | 4–35 months |
| GI/colorectal | KPS, number of brain mets | 3–17 months |
Molecular subtype profoundly impacts prognosis: EGFR-mutant or ALK-rearranged NSCLC patients with brain metastases now achieve median survival exceeding 3–4 years with targeted therapy.
Management
General Principles
Treatment of brain metastases requires a multidisciplinary approach incorporating neurosurgery, radiation oncology, medical oncology, and neurology. Key factors guiding management include: number, size, and location of metastases; primary tumor histology and molecular profile; extent of systemic disease; performance status; and patient goals of care.
Corticosteroid Management
Dexamethasone for Peritumoral Edema
- Mechanism: Reduces vasogenic edema by restoring BBB integrity; does not have direct antitumor effect (except in lymphoma)
- Dosing: Typical starting dose 4–16 mg/day in divided doses; 4 mg/day often sufficient for mild-moderate symptoms; higher doses for severe edema or herniation risk
- Onset: Clinical improvement often within 24–48 hours; imaging improvement lags behind
- Taper: Begin tapering as soon as feasible (typically over 2–4 weeks); prolonged use causes steroid myopathy, hyperglycemia, immunosuppression, Pneumocystis risk, insomnia, psychiatric disturbance, avascular necrosis
- PJP prophylaxis: Consider trimethoprim-sulfamethoxazole for patients on prolonged dexamethasone (>4 weeks or ≥4 mg/day)
- Bevacizumab: May be used as a steroid-sparing agent for radiation necrosis or refractory edema
Surgical Resection
- Indications: Large (>3 cm) symptomatic single/solitary metastasis; tissue diagnosis needed; posterior fossa lesion with hydrocephalus; acute neurologic deterioration
- Post-operative SRS to the cavity: Standard of care after resection; reduces local recurrence from ~50% to ~15–20%
- Post-operative WBRT: Reduces intracranial recurrence but at the cost of significant neurocognitive decline; largely replaced by cavity SRS in modern practice
- Contraindications: Multiple metastases, uncontrolled systemic disease, poor performance status, eloquent/inaccessible location
Stereotactic Radiosurgery (SRS)
| Aspect | Details |
|---|---|
| Mechanism | Single or fractionated high-dose, highly conformal radiation to the tumor; spares surrounding brain |
| Platforms | Gamma Knife, CyberKnife, linear accelerator (LINAC)-based SRS |
| Indications | 1–4 metastases (classic); increasingly used for up to 10–15 metastases at experienced centers |
| Size limit | Generally ≤3 cm for single-fraction SRS; larger lesions may receive fractionated SRS (3–5 fractions) |
| Local control | ~80–90% at 1 year; varies by histology (radioresistant tumors — melanoma, RCC — have lower control rates) |
| Cognitive advantage | Significantly better neurocognitive outcomes compared with WBRT (preserves hippocampal function) |
| Risk | Radiation necrosis (5–15%); may mimic tumor recurrence on imaging |
Whole-Brain Radiation Therapy (WBRT)
- Indications: Numerous (>10–15) metastases not amenable to SRS; diffuse leptomeningeal disease; as salvage after SRS failure
- Dose: Typically 30 Gy in 10 fractions
- NRG CC001 trial: Demonstrated that hippocampal-avoidance WBRT (HA-WBRT) + memantine significantly preserved cognitive function compared with standard WBRT + memantine; HA-WBRT is now the preferred technique when WBRT is indicated
- Neurocognitive toxicity: Standard WBRT causes significant delayed cognitive decline in ~50–90% of long-term survivors; this has driven the shift toward SRS when feasible
- Memantine: Started during WBRT and continued for 6 months; provides modest neuroprotection (NRG CC001)
SRS vs WBRT: Key Trials
- EORTC 22952: After surgery or SRS, adjuvant WBRT reduced intracranial recurrence but did NOT improve overall survival and worsened quality of life
- N0574 (Alliance): For 1–3 brain mets treated with SRS, adding WBRT improved intracranial control but caused significant cognitive decline at 3 months
- NRG CC001: HA-WBRT + memantine preserved cognitive function better than WBRT + memantine without compromising intracranial control
- Trend: Increasing use of SRS alone with close MRI surveillance (“SRS and watch”) to preserve neurocognition, even accepting higher distant brain failure rates
Systemic Therapy for Brain Metastases
Immunotherapy
| Histology | Regimen | Key Evidence | CNS Response Rate |
|---|---|---|---|
| Melanoma | Ipilimumab + nivolumab | CheckMate 204, ABC trial | ~55–60% intracranial response; durable responses in subset |
| Melanoma | Nivolumab monotherapy | ABC trial cohort B | ~20% (less effective than combination) |
| NSCLC | Pembrolizumab (PD-L1 ≥50%) | KEYNOTE-024/189 (brain met subgroups) | Intracranial responses observed; less data than melanoma |
| NSCLC | Nivolumab + ipilimumab | CheckMate 227 | CNS activity demonstrated in subgroup analyses |
Targeted Therapy
| Histology | Mutation/Alteration | Agent | CNS Penetration/Evidence |
|---|---|---|---|
| NSCLC | EGFR mutation | Osimertinib (3rd-gen TKI) | Excellent BBB penetration; 91% intracranial response (FLAURA); first-line standard |
| NSCLC | ALK rearrangement | Lorlatinib (3rd-gen ALK TKI) | Designed for CNS penetration; 82% intracranial response (CROWN) |
| NSCLC | ROS1 rearrangement | Lorlatinib, entrectinib | Entrectinib has demonstrated CNS activity; lorlatinib for crizotinib-resistant disease |
| Breast (HER2+) | HER2 amplification | Tucatinib + trastuzumab + capecitabine | HER2CLIMB trial: doubled intracranial PFS; FDA-approved for brain mets |
| Breast (HER2+) | HER2 amplification | Trastuzumab deruxtecan (T-DXd) | DESTINY-Breast03: CNS activity including in pretreated patients |
| Melanoma | BRAF V600E | Dabrafenib + trametinib | COMBI-MB: 58% intracranial response; responses may not be durable |
| Renal cell | Various | Cabozantinib, lenvatinib + pembrolizumab | CNS activity in retrospective series; SRS remains primary treatment |
Chemotherapy
- Traditional cytotoxic chemotherapy has limited CNS penetration and generally modest efficacy for brain metastases
- Exceptions: Temozolomide (moderate BBB penetration, used in melanoma brain mets); capecitabine (some CNS activity in breast cancer)
- The shift toward targeted therapy and immunotherapy has reduced the role of conventional chemotherapy for CNS disease in many histologies
Special Situations
Posterior Fossa Metastases
Posterior Fossa Emergencies
- Cerebellar metastases can cause acute obstructive hydrocephalus by compressing the fourth ventricle
- Symptoms: rapidly progressive headache, nausea/vomiting, truncal ataxia, altered consciousness
- Management: emergent surgical resection or external ventricular drain (EVD) for hydrocephalus; dexamethasone
- Posterior fossa lesions >3 cm typically require surgical resection rather than SRS alone due to the risk of radiation-induced edema in the confined posterior fossa
Leptomeningeal Disease (Carcinomatous Meningitis)
- Cancer cells disseminate through the CSF, coating the meninges, cranial nerves, and spinal nerve roots
- Most common primaries: Breast, lung, melanoma
- Presentation: Multifocal cranial neuropathies, radiculopathies, headache, confusion, cauda equina syndrome
- Diagnosis: CSF cytology (sensitivity 50–60% on first LP; repeat if negative), leptomeningeal enhancement on MRI (brain + spine), elevated CSF protein, low glucose
- Treatment: Intrathecal chemotherapy (methotrexate, cytarabine), radiation to symptomatic/bulky areas, systemic therapy when CNS-penetrant agents are available
- Prognosis: Historically poor (median survival 2–4 months); improving for select patients with targeted therapy-responsive histologies
Radiation Necrosis
- Delayed complication of SRS (typically 6–24 months post-treatment); incidence 5–15%
- Can be indistinguishable from tumor recurrence on standard MRI (both enhance and have surrounding edema)
- Distinguishing tools: MR perfusion (low rCBV in necrosis vs high in tumor), PET (amino acid PET preferred), surgical resection/biopsy (definitive)
- Management: Corticosteroids; bevacizumab (VEGF inhibitor) is effective for symptomatic radiation necrosis refractory to steroids; laser interstitial thermal therapy (LITT) for refractory cases
Seizure Management
Seizures in Brain Metastases
- Incidence: 15–25% at presentation; up to 40% over disease course
- Prophylactic antiseizure medication: NOT recommended in patients who have not had a seizure (AAN practice parameter)
- Preferred agents: Levetiracetam (no hepatic enzyme induction, fewer drug interactions with chemotherapy); lacosamide is an alternative
- Avoid: Enzyme-inducing ASMs (phenytoin, carbamazepine, phenobarbital) interact with many chemotherapy and targeted therapy agents
- Post-craniotomy: Short-term prophylaxis (7 days) may be reasonable; discontinue if no seizures occur
Management Algorithm by Number of Metastases
| Clinical Scenario | Primary Approach | Considerations |
|---|---|---|
| Solitary metastasis (no known primary) | Surgical resection for diagnosis + treatment; SRS to cavity | Molecular profiling of resected tissue; full body staging |
| Single metastasis, known cancer, surgically accessible | Resection + cavity SRS; OR SRS alone (if ≤3 cm) | Surgery preferred if >3 cm, symptomatic, posterior fossa, or need for tissue |
| Limited brain mets (2–4), each ≤3 cm | SRS to all lesions | Close MRI surveillance (every 2–3 months); salvage SRS for new lesions |
| Multiple brain mets (5–15) | SRS (if technically feasible) OR HA-WBRT + memantine | Expanding SRS indications; cumulative brain volume irradiated is a key consideration |
| Numerous/diffuse brain mets (>15) or miliary pattern | HA-WBRT + memantine; systemic therapy | Consider CNS-active immunotherapy or targeted therapy for responsive histologies |
| Actionable mutation (EGFR, ALK, HER2, BRAF) | CNS-penetrant targeted therapy +/− SRS | May defer radiation in asymptomatic patients with excellent systemic response |
Survivorship and Neurocognitive Considerations
- As survival improves with modern therapies, long-term neurocognitive effects of treatment become increasingly important
- WBRT-related cognitive decline: Hippocampal damage is the primary driver; affects memory, executive function, and processing speed
- Strategies to preserve cognition: SRS over WBRT when feasible, hippocampal avoidance when WBRT is necessary, memantine during and after WBRT
- Ongoing monitoring: MRI every 2–3 months initially; neurocognitive testing at baseline and follow-up; attention to quality of life and functional status
- Rehabilitation: Physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation should be integrated into survivorship care
References
- Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5.
- Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022;40(5):492-516.
- Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3773-3784.
- Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019-1029.
- Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692-1704.
- Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.
- Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609.
- Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.
- Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491.
- Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141.
- Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study (ABC). Lancet Oncol. 2018;19(5):672-681.
- Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000;54(10):1886-1893.
- Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332-1347.
- Gondi V, Bauman G, Grimm S, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348-354.